LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 7, 2024 through March 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 8, 2025.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Fortrea Holdings, Inc. ("Fortrea" or "the Company") (NASDAQ: FTRE) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July 3, 2023 and February 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 1, 2025.

Chipotle Mexican Grill is over 30% undervalued after a fear-driven sell-off, presenting a strong buy opportunity with a $63 fair value target. Recent comparable sales disappointment is overblown; positive comps returned by late Q2, and management expects mid-single-digit growth to resume. Chipotle boasts a pristine balance sheet, no long-term debt, robust cash flow, and aggressive share buybacks, ensuring financial resilience.

A Media Snippet accompanying this announcement is available by clicking on this link.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning RxSight business and prospects, resulting in its stock trading at inflated prices.

LOS ANGELES , July 28, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fiserv, Inc. ("Fiserv" or "the Company") (NYSE: FI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 24, 2024 and July 22, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.

Iconic Stars Join Princess Cruises' Celebration at Sea Featuring Meet & Greets with Original Cast, Plus Exclusive Performances by Charo FT. LAUDERDALE, Fla.

Growth has been meaningful in beverages, though a significant portion has been inorganic from the acquisition of GHOST. However, the underlying and organic trends look pretty good, and this has been coupled with a resilient performance in coffee, which is dealing with input cost inflation and price passthroughs. We think incremental earnings could support the stock, but there are political and tariff risk factors to the business under the current administration.

BREA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Bollinger Innovations, Inc. (Nasdaq: BINI) (“Bollinger Innovations” or the “Company”), an electric vehicle (“EV”) manufacturer, today announces that the Company's previously announced name change from Mullen Automotive Inc. to Bollinger Innovations, Inc. is effective July 28, 2025.

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers' Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv and certain of Fiserv's top current and former executives with violations of the Securities Exchange Act of 1934.

Experienced investors know that the clean/renewables energy industry has a long-standing reputation for political sensitivity. Said another way, there are widespread perceptions that a Democrat president is beneficial to renewable energy equities, while a Republican president can bring headwinds.

Nebius sees 385% revenue surge and eyes positive EBITDA by the second half of 2025, fueled by AI demand.

AEVA's 4D LiDAR push into infrastructure squares off with INVZ's automotive deals and stronger current revenue base.

US and EU trade representatives struck a deal to lower tariffs on EU exports to the US last night.

As the S&P 500 posts record highs, ADBE, MSFT, AMZN, and META emerge as top picks with solid earnings outlooks.

Alerus (ALRS) came out with quarterly earnings of $0.72 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.31 per share a year ago.

Could Nvidia stock (NASDAQ:NVDA) reach $300 in the next two years? There's a strong possibility.

Centene (NYSE:CNC) recently reported a surprise loss of $0.16 per share for Q2, significantly missing analyst expectations of $0.23 per share. This downturn is primarily attributed to a continued increase in medical costs for government-backed insurance plans, evidenced by a 540 basis point year-over-year surge in its health benefit ratio to 93% in Q2.

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and …